/**
 * FDA Regulatory Pathways Reference Resource
 * Comprehensive guide to FDA approval processes and requirements
 */

import { BaseResource, ResourceContent } from './base.js';
import { logger } from '../logging/index.js';

export class RegulatoryPathwaysResource extends BaseResource {
  constructor() {
    super(
      'fda://reference/regulatory-pathways',
      'FDA Regulatory Pathways Guide',
      'Comprehensive reference for FDA approval processes, timelines, and requirements across all product categories',
      'application/json'
    );
  }

  async getContent(): Promise<ResourceContent> {
    try {
      const pathwaysGuide = {
        lastUpdated: new Date().toISOString(),
        version: '2025.1',

        drugPathways: {
          nda: {
            name: 'New Drug Application (NDA)',
            description: 'Standard approval pathway for new molecular entities and new formulations',
            timeline: '10-12 months (standard), 6-8 months (priority)',
            requirements: [
              'Preclinical safety and toxicology data',
              'Phase I, II, and III clinical trial data',
              'Manufacturing information (CMC)',
              'Proposed labeling',
              'Risk evaluation and mitigation strategies (REMS) if needed'
            ],
            fees: {
              applicationFee: '$3,117,218 (2025)',
              establishmentFee: '$794,058',
              productFee: '$132,343'
            },
            success_rate: '92%',
            tips: [
              'Pre-IND meetings highly recommended',
              'End-of-Phase 2 meetings critical for Phase 3 design',
              'Consider breakthrough therapy designation for significant advances'
            ]
          },

          anda: {
            name: 'Abbreviated New Drug Application (ANDA)',
            description: 'Generic drug approval pathway demonstrating bioequivalence to reference product',
            timeline: '10 months (median)',
            requirements: [
              'Bioequivalence studies',
              'Chemistry, manufacturing, and controls data',
              'Labeling consistent with reference product',
              'Facility inspection readiness'
            ],
            fees: {
              applicationFee: '$234,516 (2025)',
              facilityFee: '$55,638',
              dmiFile: '$44,510'
            },
            success_rate: '78% (first cycle)',
            tips: [
              'Reference product selection critical',
              'Bio-waiver opportunities for certain formulations',
              'Paragraph IV certifications require careful patent analysis'
            ],
            dataResources: {
              orangeBook: {
                description: 'FDA Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations)',
                publicData: 'Patent and exclusivity information for approved drugs',
                limitations: 'No market value data or competitive analysis',
                format: 'Searchable database and downloadable files',
                url: 'https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book'
              },
              andaDatabase: {
                description: 'FDA ANDA database and approval information',
                publiclyAvailable: 'Basic ANDA approval information and status',
                limitations: 'Detailed competitive analysis requires proprietary databases',
                accessMethods: [
                  'FDA Drugs@FDA database',
                  'FDA approval letters',
                  'Generic drug approval announcements'
                ]
              }
            },
            complexGenerics: {
              description: 'Specialized generic drug development programs',
              fdaInitiatives: [
                'Complex Generic Drug Product Development Program',
                'Competitive Generic Therapy (CGT) designations',
                'Generic Drug User Fee Act (GDUFA) programs'
              ],
              categories: [
                'Liposomal formulations',
                'Peptide drugs',
                'Inhalation products',
                'Transdermal systems',
                'Modified-release formulations'
              ],
              regulatoryGuidances: 'FDA guidance documents available for complex generic development'
            },
            marketAnalysisNote: {
              limitation: 'Comprehensive market analysis and competitive intelligence are not available through public FDA APIs',
              dataGaps: 'Market size, pricing dynamics, and competitive intelligence require proprietary data sources',
              publicAlternatives: [
                'Industry reports from consulting firms',
                'Academic research studies',
                'Company annual reports and SEC filings',
                'Trade association publications'
              ]
            }
          },

          bla: {
            name: 'Biologics License Application (BLA)',
            description: 'Approval pathway for biological products including vaccines, blood products, and gene therapies',
            timeline: '12 months (standard), 6 months (priority)',
            requirements: [
              'Preclinical data demonstrating safety and activity',
              'Clinical trial data supporting safety and efficacy',
              'Manufacturing information including facility data',
              'Lot release protocols and specifications',
              'Post-market surveillance plans'
            ],
            fees: {
              applicationFee: '$3,117,218 (2025)',
              establishmentFee: '$794,058',
              productFee: '$132,343'
            },
            success_rate: '89%',
            tips: [
              'Early engagement with CBER or CDER critical',
              'Comparability protocols important for manufacturing changes',
              'Biosimilar pathway available for reference biologics'
            ]
          }
        },

        devicePathways: {
          premarket_510k: {
            name: '510(k) Premarket Notification',
            description: 'Most common device pathway demonstrating substantial equivalence to predicate device',
            timeline: '90 days (FDA goal)',
            requirements: [
              'Predicate device identification',
              'Substantial equivalence comparison',
              'Performance testing data',
              'Software documentation if applicable',
              'Labeling and user instructions'
            ],
            fees: {
              standard: '$13,934 (2025)',
              small_business: '$3,484'
            },
            success_rate: '85%',
            tips: [
              'Predicate selection is critical to success',
              'Q-Sub meetings available for complex comparisons',
              'De Novo pathway available if no suitable predicate exists'
            ]
          },

          pma: {
            name: 'Premarket Approval (PMA)',
            description: 'Most stringent device pathway for Class III devices with highest risk',
            timeline: '180 days (FDA goal)',
            requirements: [
              'Comprehensive clinical trial data',
              'Manufacturing and design controls',
              'Risk analysis and mitigation strategies',
              'Post-market study commitments',
              'Advisory panel meeting (often required)'
            ],
            fees: {
              standard: '$445,227 (2025)',
              small_business: '$111,307'
            },
            success_rate: '72%',
            tips: [
              'Pre-submission meetings essential for trial design',
              'Advisory committee preparation is crucial',
              'Post-market studies often required for approval'
            ]
          },

          de_novo: {
            name: 'De Novo Classification Request',
            description: 'Pathway for novel devices without suitable predicate for 510(k) comparison',
            timeline: '120 days (FDA goal)',
            requirements: [
              'Demonstration of device safety and effectiveness',
              'Risk classification justification',
              'Proposed special controls',
              'Clinical data (if required for risk class)',
              'Post-market study plans (if applicable)'
            ],
            fees: {
              standard: '$27,868 (2025)',
              small_business: '$6,967'
            },
            success_rate: '79%',
            tips: [
              'Establishes new device category for future 510(k)s',
              'Consider breakthrough device designation for expedited review',
              'Special controls development is key to classification'
            ]
          }
        },

        expeditedPathways: {
          breakthrough_therapy: {
            name: 'Breakthrough Therapy Designation',
            description: 'Expedited review for drugs showing substantial improvement over existing treatments',
            benefits: [
              'More frequent FDA meetings',
              'Rolling review of application components',
              'Priority review designation',
              'Enhanced FDA communication'
            ],
            criteria: 'Preliminary clinical evidence of substantial improvement on clinically significant endpoint',
            timeline_impact: 'Potential 2-4 month reduction in review time'
          },

          accelerated_approval: {
            name: 'Accelerated Approval',
            description: 'Approval based on surrogate endpoints for serious conditions with unmet medical need',
            benefits: [
              'Earlier market access',
              'Approval based on surrogate or intermediate endpoints',
              'Competitive advantage in serious diseases'
            ],
            requirements: [
              'Confirmatory trials must be conducted post-approval',
              'Regular safety updates required',
              'Withdrawal possible if confirmatory trials fail'
            ],
            timeline_impact: 'Can reduce development time by 2-5 years'
          },

          fast_track: {
            name: 'Fast Track Designation',
            description: 'Expedited development and review for drugs addressing unmet medical needs',
            benefits: [
              'More frequent FDA meetings',
              'Rolling review availability',
              'Accelerated approval eligibility',
              'Priority review if criteria met'
            ],
            criteria: 'Address unmet medical need in serious condition',
            timeline_impact: 'Enhanced FDA interaction throughout development'
          }
        },

        planningGuidance: {
          preSubmissionMeetings: [
            'Pre-IND meetings (drugs) - discuss clinical trial design',
            'End-of-Phase 2 meetings - align on Phase 3 design',
            'Pre-submission meetings (devices) - discuss regulatory strategy',
            'Q-Sub meetings - specific technical questions'
          ],

          criticalSuccessFactors: [
            'Early and frequent FDA engagement',
            'Strong preclinical and clinical data packages',
            'Robust manufacturing and quality systems',
            'Clear benefit-risk assessment',
            'Appropriate patient population selection',
            'Comprehensive regulatory strategy planning'
          ],

          commonPitfalls: [
            'Inadequate early FDA interaction',
            'Insufficient manufacturing data at submission',
            'Poor study design or execution',
            'Inadequate safety database',
            'Unclear benefit-risk profile',
            'Missing key regulatory requirements'
          ]
        },

        metadata: {
          authority: 'FDA guidance documents and CFR regulations',
          applicability: 'US market regulatory requirements',
          lastReviewed: 'January 2025',
          feeSchedule: 'FY 2025 fee schedule',
          disclaimer: 'Fees and timelines subject to annual updates. Consult current FDA guidance.'
        }
      };

      return {
        uri: this.resourceUri,
        mimeType: this.mimeType,
        text: JSON.stringify(pathwaysGuide, null, 2),
        metadata: {
          generatedAt: new Date().toISOString(),
          dataFreshness: 'reference-updated-annually',
          contentSize: JSON.stringify(pathwaysGuide).length,
          resourceType: 'regulatory-reference',
          version: pathwaysGuide.version
        }
      };

    } catch (error) {
      logger.error('Failed to generate regulatory pathways resource', error as Error, {
        component: 'REGULATORY_PATHWAYS_RESOURCE'
      });

      const errorResponse = {
        error: 'Failed to retrieve regulatory pathways guide',
        message: (error as Error).message,
        timestamp: new Date().toISOString(),
        fallbackRecommendation: 'Check FDA.gov guidance documents and CFR regulations directly'
      };

      return {
        uri: this.resourceUri,
        mimeType: this.mimeType,
        text: JSON.stringify(errorResponse, null, 2),
        metadata: {
          generatedAt: new Date().toISOString(),
          dataFreshness: 'error',
          contentSize: JSON.stringify(errorResponse).length
        }
      };
    }
  }
}